

08/470786

PATENT
9137B/GH
1.60
SC
829.95
AA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION
Hon. Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

This is a request for filing a ☒ continuation
[] divisional application under 37 CFR 1.60, of pending
prior application serial no. 07/934,667 filed on January 22,
1993 of (inventors currently of record in prior application)
John H. Bateson, George Burton, and Stephen C. M. Fell for
CEPHALOSPORINS AND HOMOLOGUES, PREPARATIONS AND
PHARMACEUTICAL COMPOSITIONS.

1. ☒ Enclosed is a copy of the prior application,
including the oath or declaration as originally
filed and an affidavit or declaration verifying it
as a true copy.
2. ☒ The filing fee is calculated below:

CLAIMS AS FILED IN THE PRIOR APPLICATION, LESS ANY
CLAIMS CANCELLED BY AMENDMENT BELOW

<u>FOR</u>	<u>NUMBER FILED</u>	<u>NUMBER EXTRA</u>	<u>RATE</u>	<u>BASIC FEE \$730.00</u>
Total Claims	11 - 20 =	-	X \$22.00	0.00
Independent Claims	1 - 3 =	-	X \$76.00	0.00
Multiple Dependent Claim(s) fee (\$240.00)				0.00
Total Filing Fee				\$730.00

9/92
M.12
(1/3)

EXPRESS MAIL NO. HB310695242 us

3. [X] Please charge Deposit Account No. 16-1445 in the amount of \$730.00. Two copies of this sheet are enclosed.
- [X] The Commissioner is hereby authorized to charge any fees which may be required under 37 C.F.R. 1.16 and 1.17, or credit any overpayment to Account No. 16-1445. Two copies of this sheet are enclosed.
4. [] Cancel in this application original claims _____, and _____ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
-
- Al* *sub* *191* 5. [X] Amend the specification by inserting before the first line the sentence: - This is a [X] continuation, [] division, of application serial no. 07/934,667, filed on January 22, 1993.
-
6. [] Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file. (May only be used if signed by person authorized by §1.138 and before payment of base issue fee.)
7. [X] Priority of application serial nos. 9016189.4 and 9109540.6 filed on (date) 07/24/90 and 05/02/91, respectively in (country) Great Britain is claimed under 35 U.S.C. 119.
- [X] The certified copy has been filed in prior application serial no. 07/934,667, filed 01/22/93.
8. [X] The prior application is assigned of record to Pfizer Inc.
9. [X] The power of attorney in the prior application is to (name, registration number, and address) Gezina Holtrust, Reg. No. 28,222, 235 East 42nd Street, New York, New York 10017-5755.
- a. [X] The power appears in the original papers in the prior application.

- b. ☐ Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c. ☒ Address all future communications to Peter C. Richardson, Pfizer Inc., 235 East 42nd Street, New York, New York 10017-5755. (May only be completed by applicant, or attorney or agent of record.)
10. ☒ A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application).
11. ☒ I hereby verify that the attached papers are a true copy of prior application serial no. 07/934,667 as originally filed on January 22, 1993.
12. ☒ Reference is made to the Information Disclosure Statement filed in the parent application citing U.S. Patent No. 3,962,223 and G.B. Patent No. 1,385,831, see enclosed PTO-1449.

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.


6/6/95
(date)

Gezina Holtrust
(signature) Gezina Holtrust

Pfizer Inc.
Patent Dept.
235 East 42nd Street
New York, N.Y. 10017-5755
(212) 573-7793

☐ Inventor(s)
☐ Assignee of complete interest
☒ Attorney of record,
Reg. No. 28,222
☐ Filed under § 1.34(a)

08/470786



EXPRESS MAIL CERTIFICATE

PFIZER DOCKET: 9137B

TITLE: CEPHALOSPORINS AND HOMOLOGUES, PREPARATIONS AND
PHARMACEUTICAL COMPOSITIONS

APPLICANT: JOHN H. BATESON ET AL.

"Express Mail" mailing label number HB310695242US

Date of Deposit JUNE 6, 1995

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, D.C. 20231.

MS. GEZINA HOLTRUST, REG. NO. 28,222

(Typed or printed name of person mailing paper or fee)

A handwritten signature in cursive script, appearing to read "Gezina Holtrust".

(Signature of person mailing paper or fee)

PFIZER INC.
PATENT DEPT.
235 East 42nd Street
NEW YORK, N.Y. 10017-5755

3/91
M.16
(1/1)